Citations

Clear

3030 citation(s) found for "Susan, M".

Childhood Apraxia of Speech: Clinical Decision Making From a Motor-Based Perspective
Stoeckel, Ruth , Caspari, Susan S. , Stoeckel, Ruth

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | June 5, 2020 | Volume: 5 | Issue: 4 | Pages: 831-842

10.1044/2020_persp-19-00090 Get It

Purpose This article uses two case studies to illustrate clinical decision making using the best available evidence to approach the assessment and intervention for children with childhood apraxia of speech. The cases represent children seen in the authors' clinical practice, with personal information altered or omitted to protect the identity of the individuals. The case discussions exemplify choices that may be made for children of different ages, highlighting common elements across ages, as well as treatment aspects that may differ by age. Conclusions While research regarding best practice for assessment and treatment for childhood apraxia of speech has not been conclusive and, in fact, at times has been equivocal, there is empirical evidence from which to develop a rationale for assessment and treatment decisions. Accountability is important even as decisions are being made based on the best available evidence. In each case study, modifications in treatment depended on data that allowed the clinician to evaluate the children's response to therapy and adapt accordingly.
Detection of zoonotic human pathogens from Ixodes scapularis in Wisconsin
Stauffer, Maxwell T., Mandli, Jordan T., Pritt, Bobbi S. , Stauffer, William M. , Sloan, Lynne M., Zembsch, Tela , Lee, Xia , Paskewitz, Susan M. , Pritt, Bobbi S

Mayo Clinic

Journal of Vector Ecology | June 3, 2020 | Volume: 45 | Issue: 1 | Pages: 147-149

10.1111/jvec.12384 | PMID 32492273 Get It

Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
Pimentel, Isabel , Chen, Bingshu E. , Lohmann, Ana Elisa , Ennis, Marguerite , Ligibel, Jennifer A. , Shepherd, Lois E. , Hershman, Dawn L. , Whelan, Timothy J. , Stambolic, Vuk , Hobday, Timothy J. , Lemieux, Julie , Thompson, Alastair, Rastogi, Priya , Rea, Daniel , Mates, Mihaela , Bédard, Philippe L. , Pitre, Lacey D. , Vandenberg, Theodore A. , Parulekar, Wendy R. , Goodwin, Pamela J. , Hobday, Timothy, Ennis, Marguerite , Chen, Bingshu E , Hershman, Dawn L , Stambolic, Vuk , Rea, Daniel W , Mayer, Ingrid A. , Gelmon, Karen A. , Rabaglio, Manuela , Ellard, Susan L. , Dowling, Ryan J.O. , Whelan, Timothy J

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 1, 2020 | Volume: 113 | Issue: 2 | Pages: 192-198

10.1093/jnci/djaa082 | PMID 33527137 Get It

Abstract Background Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex hormones. We evaluated the effect of metformin on sex hormones in MA.32, a phase III trial of nondiabetic BC subjects who were randomly assigned to metformin or placebo. Methods We studied the subgroup of postmenopausal hormone receptor-negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after being randomly assigned. Sex hormone-binding globulin, bioavailable testosterone, and estradiol levels were assayed using electrochemiluminescence immunoassay. Change from baseline to 6 months between study arms was compared using Wilcoxon sum rank tests and regression models. Results 312 women were eligible (141 metformin vs 171 placebo); the majority of subjects in each arm had T1/2, N0, HER2-negative BC and had received (neo)adjuvant chemotherapy. Mean age was 58.1 (SD=6.9) vs 57.5 (SD=7.9) years, mean body mass index (BMI) was 27.3 (SD=5.5) vs 28.9 (SD=6.4) kg/m2 for metformin vs placebo, respectively. Median estradiol decreased between baseline and 6 months on metformin vs placebo (−5.7 vs 0 pmol/L; P < .001) in univariable analysis and after controlling for baseline BMI and BMI change (P < .001). There was no change in sex hormone-binding globulin or bioavailable testosterone. Conclusion Metformin lowered estradiol levels, independent of BMI. This observation suggests a new metformin effect that has potential relevance to estrogen sensitive cancers.
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society o
Stanway, Susannah , Brezden‐Masley, Christine , Cohen‐Solal, Alain , Tocchetti, Carlo G. , Moslehi, Javid J. , Groarke, John D. , Bergler‐Klein, Jutta , Khoo, Vincent , Tan, Li Ling , Anker, Markus S. , Haehling, Stephan von , Maack, Christoph , Ky, Bonnie , Neilan, Tomas G. , Rosen, Stuart D. , Iakobishvili, Zaza , Sverdlov, Aaron L. , Hajjar, Ludhmila Abrahão , Macedo, Ariane Vieira Scarlatelli , Manisty, Charlotte , Farmakis, Dimitrios , Boer, Rudolf A. de , Skouri, Hadi , Suter, Thomas, Fradley, Michael G. , Herrmann, Joerg , Cornell, Robert F. , Wechelaker, Ashutosh, Mauro, Michael J. , Milojković, Dragana , Lavallade, Hugues de , Seferović, Petar , Chioncel, Ovidiu , Andrés, María Sol , Wright, David J. , de Boer, Rudolf A , Ky, Bonnie , Sverdlov, Aaron L , Tocchetti, Carlo Gabriele , Lyon, Alexander R. , Dent, Susan , Earl, Helena , Pudil, Radek , Barac, Ana , Thavendiranathan, Paaladinesh , Belenkov, Yu. N. , Ciardiello, Fortunato , Cardinale, Daniela , Witteles, Ronald , Ruschitzka, Frank T. , Coats, Andrew J.S. , Thum, Thomas , Bauersachs, Johann , López‐Fernández, Teresa , Plummer, Chris , Lenihan, Daniel

Mayo Clinic

European Journal of Heart Failure | May 28, 2020 | Volume: 22 | Issue: 11 | Pages: 1945-1960

10.1002/ejhf.1920 | PMID 32463967 Get It

Abstract This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Re: “Issues Faced by Senior Women Physicians: A National Survey,” by Templeton K, et al.
Englander, Meridith J. , Gebhard, Roberta E., Moeschler, Susan M. , Sharkey, Katherine M. , Jain, Shikha , Silver, Julie K.

Mayo Clinic

Journal of Women's Health | May 26, 2020 | Volume: 29 | Issue: 8 | Pages: 1136-1136

10.1089/jwh.2020.8346 | PMID 32453618 Get It

Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations
Vega, Leticia R. , Primus, Clara, Etson, Candice M. , Guillory, Ashley N. , Edwards, Ashanti, Flores, Sonia C., Fry, Catherine, Ingram, Susan , Lawson, Mark A. , McGee, Richard , Paxson, Stephanie, Phelan, Laura, Suggs, Kirsta, Vuong, Elizabeth, Hammonds-Odie, Latanya , Leibowitz, Michael J. , Zavala, MariaElena, Luján, J. Luis , Ramirez-Alvarado, Marina, Segarra, Verónica A. , Ramı́rez-Alvarado, Marina

Mayo Clinic

CBE—Life Sciences Education | May 26, 2020 | Volume: 19 | Issue: 2 | Pages: es3

10.1187/cbe.19-11-0262 | PMID 32453676 Get It

This essay compares the approaches that scientific societies in the ACCESS meta-organization use to implement and assess travel award programs for URM trainees and presents a set of recommendations, including both short- and long-term outcomes assessment in populations of interest and specialized programmatic activities coupled to travel award programs.
Emergence From the COVID-19 Pandemic and the Care of Chronic Pain: Guidance for the Interventionalist
Pope, Jason E. , Petersen, Erika , Moeschler, Susan M. , Amirdelfan, Kasra , Workgroup, the ASPN COVID, Deer, Timothy R. , Sayed, Dawood , Chakravarthy, Krishnan V , Abd-Elsayed, Alaa A , Mekhail, Nagy , Workgroup, the ASPN COVID

Mayo Clinic

Anesthesia & Analgesia | May 25, 2020 | Volume: 131 | Issue: 2 | Pages: 387-394

10.1213/ane.0000000000005000 | PMID 32452905 Get It

BACKGROUND: The current coronavirus disease 2019 (COVID-19) pandemic led to a significant disruption in the care of pain from chronic and subacute conditions. The impact of this cessation of pain treatment may have unintended consequences of increased pain, reduced function, increased reliance on opioid medications, and potential increased morbidity, due to the systemic impact of untreated disease burden. This may include decreased mobility, reduction in overall health status, and increase of opioid use with the associated risks. METHODS: The article is the study of the American Society of Pain and Neuroscience (ASPN) COVID-19 task force to evaluate the policies set forth by federal, state, and local agencies to reduce or eliminate elective procedures for those patients with pain from spine, nerve, and joint disease. The impact of these decisions, which were needed to reduce the spread of the pandemic, led to a delay in care for many patients. We hence review an emergence plan to reinitiate this pain-related care. The goal is to outline a path to work with federal, state, and local authorities to combat the spread of the pandemic and minimize the deleterious impact of pain and suffering on our chronic pain patients. RESULTS: The article sets forth a strategy for the interventional pain centers to reemerge from the current pandemic and to set a course for future events. CONCLUSIONS: The COVID-19 pandemic represents an overwhelming challenge to interventional pain physicians and their patients. In addition to urgent actions needed for disease mitigation, the ASPN recommends a staged return to pain management professionals’ workflow.
Nasal vestibulitis: An MNCCTN natural history trial—Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents.
Zahrieh, David , Smith, Deanne s., Young, Susan E. , Wolfe, Eric, Thomé, Stephan D. , Register, Terra, Piens, Jill, McCue, Shaylene , Loprinzi, Charles L. , Cathcart-Rake, Elizabeth , Young, Susan, O'Connor, Amanda, Lacouture, Mario E.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24086-e24086

10.1200/jco.2020.38.15_suppl.e24086 Get It

e24086 Background: Nasal vestibulitis has been infrequently described as a side effect of cancer-directed therapy; however, a preliminary study reported that 71% of patients undergoing taxane chemotherapy experienced nasal vestibulitis symptoms. This natural history trial describes the incidence, characteristics, and severity of nasal vestibulitis symptoms among patients undergoing paclitaxel, docetaxel, and non-taxane chemotherapy. Methods: Eligible participants who reported baseline (prior to starting chemotherapy) nasal symptoms ≤ 2 on a 10-point scale were enrolled in this trial upon initiation of a new treatment regimen, involving paclitaxel or docetaxel, or non-taxane chemotherapy. Participants completed nasal symptom logs each time they received a dose of therapy until either the regimen was stopped or four months had passed. The proportion of patients reporting new nasal symptoms was estimated within each cohort with the 95% exact confidence interval (CI). A cumulative incidence model was utilized to quantify the incidence of treatment-emergent nasal symptoms within each cohort, while controlling for age, sex, smoking history, and history of asthma or allergies. Results: Thirty-five participants received paclitaxel, 21 received docetaxel, and 25 received other types of chemotherapy. 86.4% of participants were female, mean age was 60.2 ± 11.2 years; 93.8% of participants completed 2 or more surveys. A higher percentage of participants in the paclitaxel cohort experienced new nasal vestibulitis symptoms than participants in the other two cohorts. The percentage (95% CI) of participants with nasal symptoms, for patients receiving paclitaxel, docetaxel, and non-taxane chemotherapy were 74.3% (56.7%, 87.5%), 47.6% (25.7%, 70.2%), and 44.0% (24.4%, 65.1%), respectively. Epistaxis was reported by 60% of participants in the paclitaxel cohort. Paclitaxel-receiving participants also reported nasal dryness (48.6%), scabbing (40.0%), and pain (20.0%). Nearly half of participants reported moderate symptoms (4-7 out of a 10-point scale), with 8.6% reporting symptoms as severe (8-10 on a 10-point scale). Conclusions: Nasal vestibulitis is a common side effect of chemotherapy, especially paclitaxel chemotherapy.